AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03398265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
Study NCT02833792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Mesenchymal Stem Cells and Lactated Riunger's Solution
Description: Intravenous administration
Study NCT02833792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study NCT03908645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assisted bowel preparation quality scoring system
Description: After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
Study NCT03908645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional human scoring
Description: After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
Study NCT01582737 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban(Xarelto, BAY59-7939)
Description: Patients treated with Xarelto under practical manner
Study NCT01497821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 172
Description: AMG 172 is an antibody drug conjugate
Study NCT03285958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS Intervention
Description: Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
Study NCT01316952 — intervention group
Intervention type: DRUG
Intervention: Carvedilol immediate release only
Description: All dosages of carvedilol immediate release
Study NCT01316952 — intervention group
Intervention type: DRUG
Intervention: Carvedilol extended release only
Description: All dosages of carvedilol extended release
Study NCT01316952 — intervention group
Intervention type: DRUG
Intervention: Long acting β-blockers
Description: All dosages of LA propranolol and SA metoprolol
Study NCT01316952 — intervention group
Intervention type: DRUG
Intervention: Other α1/β-adrenergic antagonists
Description: i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
Study NCT01316952 — intervention group
Intervention type: DRUG
Intervention: Short acting Non-selective β-blockers and short acting β1-Selective agents
Description: All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
Study NCT01316952 — intervention group
Intervention type: OTHER
Intervention: No β-blocker
Description: No β-blocker within the month prior to the index date
Study NCT03050762 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Participant information collected from either source document or direct participant response.
Study NCT03050762 — intervention group
Intervention type: BEHAVIORAL
Intervention: Follow Up
Description: Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
Study NCT00663286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-110
Description: Topical application for 12 weeks
Study NCT00663286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Topical application for 12 weeks
Study NCT00663286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide
Description: Topical application for 12 weeks
Study NCT00663286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application for 12 weeks
Study NCT00662376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PreOP Booster (oral nutritional supplement, food for special medical purposes)
Description: 3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
Study NCT00662376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP Booster (oral nutritional supplement, food for special medical purposes)
Description: 3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
Study NCT01001546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based
Description: Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
Study NCT01001546 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Clinic-Based
Description: Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
Study NCT00287937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00287937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00287937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00287937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00287937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01329614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Training
Description: Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
Study NCT01329614 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Extinction Training
Description: Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
Study NCT01329614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
Study NCT01329614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Extinction Therapy
Description: Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Study NCT01137045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SPEEDA and TRCS SPEEDA
Description: For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.~For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.~For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI
Study NCT01982747 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MGN-Placebo
Study NCT01982747 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo-MGN
Study NCT02432846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intuvax (INN: ilixadencel)
Description: Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
Study NCT02432846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Cytostatic/cytotoxic drug: protein kinase inhibitor .
Study NCT02432846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Cytostatic/cytotoxic drug: protein kinase inhibitor .
Study NCT04585022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnum, Zimmer Biomet, Warsaw, IN
Study NCT04585022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recap, Zimmer Biomet, Warsaw, IN
Study NCT01329614 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Extinction Therapy
Description: Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Study NCT01329614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Study NCT01912287 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT focused on Generalized Anxiety Disorder (12 sessions)
Study NCT01912287 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stress Education
Description: Active control group (12 sessions)
Study NCT01912287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 sessions, mindfulness components
Study NCT02127567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online writing tool
Description: The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
Study NCT02127567 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: writing with no specific support
Description: The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
Study NCT03103919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesia-ONE™
Description: Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
Study NCT03103919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia-ONE™
Description: Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
Study NCT03103919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia-360™
Description: Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
Study NCT03103919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine
Description: All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
Study NCT03103919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
Study NCT00941018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10001
Description: RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
Study NCT01329614 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Study NCT05909774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test with Atalante exoskeleton in continuous walk type
Description: The continuous walk is smoother and more physiologic than the push and swing walk
Study NCT00758082 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paper support
Description: Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
Study NCT00758082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDA-phone + telemonitoring
Description: Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
Study NCT03453684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Vancomycin
Description: Intravenous Vancomycin Administration
Study NCT02963207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Sano's classification
Description: Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
Study NCT02963207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NICE classification
Description: Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
Study NCT04237441 — intervention group
Intervention type: OTHER
Intervention: number of participants with surgical complications
Description: observation before and after multidisplinary team conference (MDT) was implemented
Study NCT02024867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: 3 versus 10 days of drug
Study NCT02024867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole
Description: 3 versus 10 days of drug
Study NCT04751344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
Study NCT04751344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
Study NCT02506140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Acetylsalicylic acid
Description: This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
Study NCT02506140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel and Acetylsalicylic acid
Description: This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
Study NCT04053959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI assisted insulin system
Description: The patients receive the insulin regime set by AI assisted insulin titration system
Study NCT04053959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician based insulin regime
Description: Patients receive the insulin regime recommended by physicians
Study NCT05909774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test with Atalante exoskeleton in continuous walk type
Description: The continuous walk is smoother and more physiologic than the push and swing walk
Study NCT02374658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Through the Arts Intervetion
Description: A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
Study NCT01726673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Study NCT01726673 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sham
Study NCT01788579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-media WINGS
Description: This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
Study NCT01788579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caseworker Delivered WINGS
Description: The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
Study NCT03730766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT03730766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication
Study NCT03730766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT00984607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: barium sulfate tablet
Description: After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
Study NCT02753686 — intervention group
Intervention type: DRUG
Intervention: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
Study NCT02753686 — intervention group
Intervention type: DRUG
Intervention: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
Study NCT02702531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloShield Defogging and Cleaning System
Study NCT02370095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treprostinil Inhalation Solution
Description: Treprostinil inhalation solution administered as blinded marketed product
Study NCT02370095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil